CIPHER PHARMACEUTICALS INC (CPH.CA) Fundamental Analysis & Valuation

TSX:CPH • CA17253X1050

Current stock price

18.8 CAD
+0.52 (+2.84%)
Last:

This CPH.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. CPH.CA Profitability Analysis

1.1 Basic Checks

  • CPH had positive earnings in the past year.
  • In the past year CPH had a positive cash flow from operations.
  • CPH had positive earnings in 4 of the past 5 years.
  • Of the past 5 years CPH 4 years had a positive operating cash flow.
CPH.CA Yearly Net Income VS EBIT VS OCF VS FCFCPH.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • The Return On Assets of CPH (11.77%) is better than 90.91% of its industry peers.
  • The Return On Equity of CPH (15.23%) is better than 87.88% of its industry peers.
  • CPH's Return On Invested Capital of 7.23% is amongst the best of the industry. CPH outperforms 87.88% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for CPH is in line with the industry average of 8.22%.
Industry RankSector Rank
ROA 11.77%
ROE 15.23%
ROIC 7.23%
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
CPH.CA Yearly ROA, ROE, ROICCPH.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

1.3 Margins

  • CPH's Profit Margin of 34.68% is amongst the best of the industry. CPH outperforms 100.00% of its industry peers.
  • CPH's Profit Margin has improved in the last couple of years.
  • CPH has a better Operating Margin (25.51%) than 84.85% of its industry peers.
  • In the last couple of years the Operating Margin of CPH has declined.
  • CPH's Gross Margin of 74.32% is amongst the best of the industry. CPH outperforms 93.94% of its industry peers.
  • In the last couple of years the Gross Margin of CPH has declined.
Industry RankSector Rank
OM 25.51%
PM (TTM) 34.68%
GM 74.32%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
CPH.CA Yearly Profit, Operating, Gross MarginsCPH.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CPH.CA Health Analysis

2.1 Basic Checks

  • CPH has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • There is no outstanding debt for CPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CPH.CA Yearly Shares OutstandingCPH.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
CPH.CA Yearly Total Debt VS Total AssetsCPH.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • CPH has an Altman-Z score of 7.62. This indicates that CPH is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of CPH (7.62) is better than 93.94% of its industry peers.
  • The Debt to FCF ratio of CPH is 0.45, which is an excellent value as it means it would take CPH, only 0.45 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 0.45, CPH belongs to the best of the industry, outperforming 93.94% of the companies in the same industry.
  • CPH has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of CPH (0.12) is better than 69.70% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 0.45
Altman-Z 7.62
ROIC/WACC0.87
WACC8.29%
CPH.CA Yearly LT Debt VS Equity VS FCFCPH.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 1.30 indicates that CPH should not have too much problems paying its short term obligations.
  • CPH has a worse Current ratio (1.30) than 69.70% of its industry peers.
  • CPH has a Quick Ratio of 1.30. This is a bad value and indicates that CPH is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.98, CPH is doing worse than 60.61% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 0.98
CPH.CA Yearly Current Assets VS Current LiabilitesCPH.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CPH.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 126.09% over the past year.
  • The Earnings Per Share has been growing by 43.65% on average over the past years. This is a very strong growth
EPS 1Y (TTM)126.09%
EPS 3YN/A
EPS 5Y43.65%
EPS Q2Q%292.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.35%

3.2 Future

  • CPH is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -11.86% yearly.
  • CPH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.62% yearly.
EPS Next Y-42.22%
EPS Next 2Y-11.86%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.09%
Revenue Next 2Y17.62%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CPH.CA Yearly Revenue VS EstimatesCPH.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
CPH.CA Yearly EPS VS EstimatesCPH.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 1 -1

More info and screens

Find the best growth stocksShow best growing peers

4

4. CPH.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 12.97 indicates a correct valuation of CPH.
  • Compared to the rest of the industry, the Price/Earnings ratio of CPH indicates a somewhat cheap valuation: CPH is cheaper than 78.79% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 25.60. CPH is valued slightly cheaper when compared to this.
  • The Price/Forward Earnings ratio is 22.49, which indicates a rather expensive current valuation of CPH.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of CPH indicates a somewhat cheap valuation: CPH is cheaper than 66.67% of the companies listed in the same industry.
  • CPH's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.84.
Industry RankSector Rank
PE 12.97
Fwd PE 22.49
CPH.CA Price Earnings VS Forward Price EarningsCPH.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CPH is on the same level as its industry peers.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of CPH indicates a somewhat cheap valuation: CPH is cheaper than 72.73% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 11.42
EV/EBITDA 17.59
CPH.CA Per share dataCPH.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The decent profitability rating of CPH may justify a higher PE ratio.
  • CPH's earnings are expected to decrease with -11.86% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)0.3
EPS Next 2Y-11.86%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CPH.CA Dividend Analysis

5.1 Amount

  • No dividends for CPH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CPH.CA Fundamentals: All Metrics, Ratios and Statistics

CIPHER PHARMACEUTICALS INC

TSX:CPH (4/2/2026, 7:00:00 PM)

18.8

+0.52 (+2.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-12
Earnings (Next)05-06
Inst Owners1.32%
Inst Owner ChangeN/A
Ins Owners3.63%
Ins Owner ChangeN/A
Market Cap475.26M
Revenue(TTM)N/A
Net Income(TTM)17.36M
Analysts77.5
Price Target19.92 (5.96%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.24%
Min EPS beat(2)36.14%
Max EPS beat(2)66.34%
EPS beat(4)2
Avg EPS beat(4)14.52%
Min EPS beat(4)-37.21%
Max EPS beat(4)66.34%
EPS beat(8)5
Avg EPS beat(8)34.73%
EPS beat(12)9
Avg EPS beat(12)113.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.76%
Min Revenue beat(2)-6.01%
Max Revenue beat(2)2.48%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)2.48%
Revenue beat(8)2
Avg Revenue beat(8)-0.16%
Revenue beat(12)3
Avg Revenue beat(12)1.53%
Revenue beat(16)3
Avg Revenue beat(16)-1.19%
PT rev (1m)1.74%
PT rev (3m)8.37%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.21%
Valuation
Industry RankSector Rank
PE 12.97
Fwd PE 22.49
P/S 6.83
P/FCF 11.42
P/OCF 11.39
P/B 3
P/tB 14.96
EV/EBITDA 17.59
EPS(TTM)1.45
EY7.71%
EPS(NY)0.84
Fwd EY4.45%
FCF(TTM)1.65
FCFY8.75%
OCF(TTM)1.65
OCFY8.78%
SpS2.75
BVpS6.27
TBVpS1.26
PEG (NY)N/A
PEG (5Y)0.3
Graham Number14.3
Profitability
Industry RankSector Rank
ROA 11.77%
ROE 15.23%
ROCE 10.05%
ROIC 7.23%
ROICexc 7.75%
ROICexgc 33.36%
OM 25.51%
PM (TTM) 34.68%
GM 74.32%
FCFM 59.76%
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score7
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 0.45
Debt/EBITDA 0.67
Cap/Depr 1.2%
Cap/Sales 0.17%
Interest Coverage 250
Cash Conversion 152.24%
Profit Quality 172.34%
Current Ratio 1.3
Quick Ratio 0.98
Altman-Z 7.62
F-Score7
WACC8.29%
ROIC/WACC0.87
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)126.09%
EPS 3YN/A
EPS 5Y43.65%
EPS Q2Q%292.31%
EPS Next Y-42.22%
EPS Next 2Y-11.86%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.35%
Revenue Next Year3.09%
Revenue Next 2Y17.62%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.19%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year139.63%
EBIT Next 3Y44.89%
EBIT Next 5YN/A
FCF growth 1Y98.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.32%
OCF growth 3Y12.28%
OCF growth 5Y19.77%

CIPHER PHARMACEUTICALS INC / CPH.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?

ChartMill assigns a fundamental rating of 5 / 10 to CPH.CA.


Can you provide the valuation status for CIPHER PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 4 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Fairly Valued.


Can you provide the profitability details for CIPHER PHARMACEUTICALS INC?

CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 7 / 10.


What is the earnings growth outlook for CIPHER PHARMACEUTICALS INC?

The Earnings per Share (EPS) of CIPHER PHARMACEUTICALS INC (CPH.CA) is expected to decline by -42.22% in the next year.